Dr. Michael Thiel publishes Part III of the three-part series on venture capital in the German life-science-industry for the journal pharmind. The focus is on the consideration of institutional venture-capital-funds, which are the largest and most important investors for life science start-ups. An overview of selected European and German life science venture-capital-funds should clarify the backlog for venture capital in Germany. Finally, the investment strategies of the funds and investment opportunities for interested investors are presented.

You can find the whole article here  (German-language link)